Bayer says its experimental blood thinner cuts risk and severity of repeat strokes

Bayer AG

06/05/2026 09:30

May 6 (Reuters) - Bayer BAYGn.DE said on Wednesday new analyses showed its experimental blood thinner asundexian reduced the incidence and severity of ischaemic strokes.

Data from a phase III trial showed fewer ischaemic strokes occurred with the drug (6.2%) compared with placebo (8.4%) in patients who have suffered a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack.

 (Reporting by Patricia Weiss, writing by Linda Pasquini, editing by Kirsti Knolle)

 ((linda.pasquini@thomsonreuters.com; +48 58 7785261;))